LONDON, July 27, 2017 /PRNewswire/ -- Biologics market covers biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnology methods and other cutting-edge technologies. Download the full report: https://www.reportbuyer.com/product/5013143/The global biologics market was estimated to be around $210 billion as of 2016. It made up around 20% of the overall pharmaceuticals market in 2016. The biologics was the second largest market, following the pharmaceutical drugs market in the global pharmaceutical market in 2016.Treatment of complex diseasesBiologics provide effective treatment for many complex diseases such as Rheumatoid arthritis that have less treatment options. There has been significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Download the full report: https://www.reportbuyer.com/product/5013143/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/biologics-market-global-report-2017-300495596.html
SOURCE ReportBuyer
